

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the Specification:**

Paragraph beginning at line 17 of page 4 has been amended as follows:

Fig. 2 shows the location of two peptides I-A<sup>s</sup>β p18mer (SEQ ID NO:1) and I-A<sup>s</sup>β p10mer (SEQ ID NO:2) and their location in the third hypervariable region of the β chain of I-A<sup>s</sup>.

Paragraph beginning at line 25 of page 34 has been amended as follows:

DR4/1-Peptide amino acid sequence from N-terminus to C-terminus:

Acetyl-L-Asp-Ala-Glu-Tyr-Trp-Asn-Ser-Gln-Lys-Asp-Leu-Leu-Glu-Gln-Lys-Arg-Ala-Ala-Val-Asp (SEQ ID NO:3).

**In the Claims:**

Claims 7, 20, 32 and 44 have been amended as follows:

7. (Amended) The composition of claim 1, wherein the isolated immunogenic MHC polypeptide comprises an amino acid sequence Asp-Ala-Glu-Tyr-Trp-Asn-Ser-Gln-Lys-Asp-Leu-Leu-Glu-Gln-Lys-Arg-Ala-Ala-Val-Asp (SEQ ID NO:4).

20. (Amended) The pharmaceutical composition of claim 15, wherein the immunogenic MHC polypeptide comprises the amino acid sequence Asp-Ala-Glu-Tyr-Trp-Asn-Ser-Gln-Lys-Asp-Leu-Leu-Glu-Gln-Lys-Arg-Ala-Ala-Val-Asp (SEQ ID NO:4).

32. (Amended) The method of claim 24, wherein the immunogenic MHC polypeptide comprises the amino acid sequence Asp-Ala-Glu-Tyr-Trp-Asn-Ser-Gln-Lys-Asp-Leu-Leu-Glu-Gln-Lys-Arg-Ala-Ala-Val-Asp (SEQ ID NO:4).

44. (Amended) The method of claim 39, wherein the immunogenic polypeptide comprises the amino acid sequence Asp-Ala-Glu-Tyr-Trp-Asn-Ser-Gln-Lys-Asp-Leu-Leu-Glu-Gln-Lys-Arg-Ala-Ala-Val-Asp (SEQ ID NO:4).